OncoResponse Inc. is an immuno-oncology company based in Houston, Texas, focused on discovering new cancer immunotherapies and therapeutic antibodies. The company collaborates with MD Anderson Cancer Center to utilize the I-STAR™ platform, which analyzes the human memory B-cell repertoire of patients who have demonstrated exceptional responses to immunotherapy, referred to as "Elite Responders." By studying these patients, OncoResponse aims to harness the human immune system to identify fully human monoclonal antibodies and novel targets. This approach is intended to facilitate the development of innovative antibody-derived therapeutics for cancer treatment.
Geneos Therapeutics, Inc. specializes in the production and development of neoantigen-targeting cancer immunotherapies. Founded in 2016 and based in Plymouth Meeting, Pennsylvania, the company utilizes its Geneos Platform to create personalized therapies that are specifically tailored to the unique tumor mutations of each patient. By identifying relevant neoantigen targets from individual tumors, Geneos aims to develop innovative treatments that provide targeted immunotherapies for cancer patients, enhancing the potential for effective disease management and cure.
NeoPhore is a provider of novel small molecule therapies intended to treat cancer through stimulation of the immune system.The company's small molecule therapies target genetic mechanisms in order to create neoantigen which is known to stimulate the immune system and potentially be a weak spot in a tumor cell's defense mechanisms, enabling cancer patients to get treated and achieve improved clinical outcomes.
Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G Protein-Coupled Receptors (GPCRs), which are key drug targets in various diseases. The company specializes in developing treatments for Central Nervous System (CNS) disorders and cancer. Utilizing its proprietary DTect-All technology, Domain Therapeutics identifies both orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs), which are not discoverable through conventional methods. This innovative approach allows the company to address challenging GPCRs, including orphan and peptidic receptors. Founded in 2001, the company was previously known as Faust Pharmaceuticals SA before rebranding in December 2008.
Kither Biotech s.r.l. is a pharmaceutical company based in Turin, Italy, focused on the research and development of drugs and therapies for pulmonary diseases. Founded in 2011, the company is dedicated to addressing unmet medical needs in chronic inflammatory conditions. Its main products include the KIT2014 peptide, developed internally for the treatment of cystic fibrosis, which has received Orphan Drug designation from the European Medicines Agency and is currently in the pre-clinical development phase. Additionally, Kither is advancing the development of a molecule known as CL27, aimed at treating chronic obstructive pulmonary diseases and allergic asthma, and is preparing to enter its pre-clinical phase. Through its innovative research efforts, Kither Biotech seeks to provide effective treatments for patients suffering from various respiratory diseases.
IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor.
GenEp, Inc. is a pre-clinical stage biotechnology company based on intellectual property assets. GenEp creates therapies targeting mutations of sodium and other ion channels that cause rare genetic epilepsies and other treatment-resistant epilepsies.
GreenBone develops a wood-derived bone implants technology to generate biomimetic – reabsorbable– load bearing implant suitable to address non-union fractures. The idea was conceived and developed by a research group of ISTEC-CNR of Faenza comprised of Andrea Ruffini, Simone Sprio and Anna Tampieri.
OncoResponse Inc. is an immuno-oncology company based in Houston, Texas, focused on discovering new cancer immunotherapies and therapeutic antibodies. The company collaborates with MD Anderson Cancer Center to utilize the I-STAR™ platform, which analyzes the human memory B-cell repertoire of patients who have demonstrated exceptional responses to immunotherapy, referred to as "Elite Responders." By studying these patients, OncoResponse aims to harness the human immune system to identify fully human monoclonal antibodies and novel targets. This approach is intended to facilitate the development of innovative antibody-derived therapeutics for cancer treatment.
On Target Laboratories, LLC engages in discovering, developing, and commercializing small molecules that target specific pathological cells, when conjugated with fluorescent dyes. It offers folate and other targeting agents that target, lung, uterine, kidney, breast, colon, pancreatic, and prostate cancer cells. The company was incorporated in 2010 and is based in Northbrook, Illinois.
NeoPhore is a provider of novel small molecule therapies intended to treat cancer through stimulation of the immune system.The company's small molecule therapies target genetic mechanisms in order to create neoantigen which is known to stimulate the immune system and potentially be a weak spot in a tumor cell's defense mechanisms, enabling cancer patients to get treated and achieve improved clinical outcomes.
iOnctura SA is a biopharmaceutical company based in Geneva, Switzerland, founded in 2017. The company focuses on developing innovative therapeutics aimed at modulating immunosuppression within the tumor microenvironment, which is a significant barrier to effective cancer treatment. Its product pipeline includes selective Pi3K inhibitors, Anti-Lag 3 antibodies, ATX inhibitors, Anti-CXCL12 antibodies, and Anti-CD73 antibodies. iOnctura aims to enhance the efficacy of existing immune checkpoint therapies by creating novel drugs that, when used in combination with these therapies, can optimize clinical outcomes for cancer patients. The company has formed partnerships with Merck and Cancer Research Technology, leveraging their resources to advance its preclinical molecules and establish promising combination therapies within cancer immunology. Supported by a distinguished scientific advisory board, iOnctura is well-positioned to innovate in the rapidly evolving field of cancer treatment.
Gain Therapeutics is a biotechnology company focused on developing pharmacological chaperones to address rare metabolic disorders and other diseases. Established in 2017 and headquartered in Bethesda, Maryland, the company is dedicated to innovating drug therapies, particularly for lysosomal storage disorders, central nervous system disorders, and metabolic conditions. Its clinical-stage candidate, GT-02287, targets GBA1 Parkinson's disease. Gain Therapeutics employs a computational platform called Magellan to discover novel allosteric binding sites on disease-related proteins, enabling the identification of proprietary small molecules that can enhance protein function and address the root causes of various diseases. By developing targeted therapies, the company aims to meet significant unmet medical needs, particularly in pediatric genetic disorders.
Amal Therapeutics SA is a biotech company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company focuses on the research and development of therapeutic vaccines for oncology, utilizing its proprietary cell penetrating peptide platform. Amal Therapeutics aims to create innovative therapeutic cancer vaccines and immunotherapies to enhance treatment options for cancer patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.
OncoResponse Inc. is an immuno-oncology company based in Houston, Texas, focused on discovering new cancer immunotherapies and therapeutic antibodies. The company collaborates with MD Anderson Cancer Center to utilize the I-STAR™ platform, which analyzes the human memory B-cell repertoire of patients who have demonstrated exceptional responses to immunotherapy, referred to as "Elite Responders." By studying these patients, OncoResponse aims to harness the human immune system to identify fully human monoclonal antibodies and novel targets. This approach is intended to facilitate the development of innovative antibody-derived therapeutics for cancer treatment.
NovellusDx, Ltd. is a biotechnology company based in Jerusalem, Israel, established in 2011 by Haim Gil-ad and Yoram Altschuler. The company specializes in developing targeted therapies for cancer patients by focusing on tumor-specific driver mutations. NovellusDx utilizes innovative testing methods to evaluate the effectiveness of targeted therapy drugs on emulated tumors, allowing for the quantification of therapeutic effects. The company also monitors the oncogenic activity of relevant genes and proteins in patients, assessing changes before and after drug administration. Additionally, NovellusDx develops assays to detect the misregulated translocation of mutated signaling proteins to the nucleus, measuring the impact of drug candidates on specific tumors, particularly concerning their ability to inhibit the translocation of up-regulated signaling proteins.
On Target Laboratories, LLC engages in discovering, developing, and commercializing small molecules that target specific pathological cells, when conjugated with fluorescent dyes. It offers folate and other targeting agents that target, lung, uterine, kidney, breast, colon, pancreatic, and prostate cancer cells. The company was incorporated in 2010 and is based in Northbrook, Illinois.
Personal Genome Diagnostics develops a patient-specific analysis of the cancer genome by using advanced tools and technologies. They were the first to sequence and analyze whole human cancer exomes and subsequently identified many alterations responsible for the development of cancer. They have described the principles underlying the genetic basis of human cancer and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Through PGDx, our founders bring their proprietary methods and expertise to research teams worldwide. The services help oncologists and translational scientists sequence and analyze cancer genomes and identify mutations to characterize aspects of the disease. Their expertise in genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. They specialize in high-throughput next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Personal Genome Diagnostics was founded in 2010 and is based in Baltimore, Maryland, United States.
QuantuMDx Group Limited is a medical devices company that specializes in developing portable and affordable diagnostic tools for use in various healthcare settings, including clinics, pharmacies, hospitals, and laboratories. Founded in 2008 and based in Newcastle upon Tyne, United Kingdom, with subsidiaries in the United States and Singapore, the company offers products such as Q-POC, a battery-operated molecular diagnostic device that delivers sample-to-result testing in 10 to 30 minutes for various biological samples. QuantuMDx's diagnostic solutions are applicable in areas such as warfarin prediction, HPV diagnostics, drug susceptibility testing, and sexually transmitted infection panel testing. Additionally, the company has developed the Internet of Life, a real-time global pathogen monitoring system, aimed at enhancing disease detection and management. QuantuMDx's innovations support personalized medicine, making advanced diagnostics accessible in both developed and developing nations.
Amal Therapeutics SA is a biotech company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company focuses on the research and development of therapeutic vaccines for oncology, utilizing its proprietary cell penetrating peptide platform. Amal Therapeutics aims to create innovative therapeutic cancer vaccines and immunotherapies to enhance treatment options for cancer patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.
GreenBone develops a wood-derived bone implants technology to generate biomimetic – reabsorbable– load bearing implant suitable to address non-union fractures. The idea was conceived and developed by a research group of ISTEC-CNR of Faenza comprised of Andrea Ruffini, Simone Sprio and Anna Tampieri.
QuantuMDx Group Limited is a medical devices company that specializes in developing portable and affordable diagnostic tools for use in various healthcare settings, including clinics, pharmacies, hospitals, and laboratories. Founded in 2008 and based in Newcastle upon Tyne, United Kingdom, with subsidiaries in the United States and Singapore, the company offers products such as Q-POC, a battery-operated molecular diagnostic device that delivers sample-to-result testing in 10 to 30 minutes for various biological samples. QuantuMDx's diagnostic solutions are applicable in areas such as warfarin prediction, HPV diagnostics, drug susceptibility testing, and sexually transmitted infection panel testing. Additionally, the company has developed the Internet of Life, a real-time global pathogen monitoring system, aimed at enhancing disease detection and management. QuantuMDx's innovations support personalized medicine, making advanced diagnostics accessible in both developed and developing nations.
Aadi Bioscience, Inc. is a clinical stage biopharmaceutical company based in Pacific Palisades, California, founded by Dr. Neil Desai in 2011. The company focuses on the development of a potentially best-in-class mTOR inhibitor, specifically ABI-009, aimed at treating patients with oncology, cardiovascular, and metabolic diseases. Aadi Bioscience is dedicated to addressing unmet medical needs through its innovative therapeutic approaches in these areas.
OncoResponse Inc. is an immuno-oncology company based in Houston, Texas, focused on discovering new cancer immunotherapies and therapeutic antibodies. The company collaborates with MD Anderson Cancer Center to utilize the I-STAR™ platform, which analyzes the human memory B-cell repertoire of patients who have demonstrated exceptional responses to immunotherapy, referred to as "Elite Responders." By studying these patients, OncoResponse aims to harness the human immune system to identify fully human monoclonal antibodies and novel targets. This approach is intended to facilitate the development of innovative antibody-derived therapeutics for cancer treatment.
QuantuMDx Group Limited is a medical devices company that specializes in developing portable and affordable diagnostic tools for use in various healthcare settings, including clinics, pharmacies, hospitals, and laboratories. Founded in 2008 and based in Newcastle upon Tyne, United Kingdom, with subsidiaries in the United States and Singapore, the company offers products such as Q-POC, a battery-operated molecular diagnostic device that delivers sample-to-result testing in 10 to 30 minutes for various biological samples. QuantuMDx's diagnostic solutions are applicable in areas such as warfarin prediction, HPV diagnostics, drug susceptibility testing, and sexually transmitted infection panel testing. Additionally, the company has developed the Internet of Life, a real-time global pathogen monitoring system, aimed at enhancing disease detection and management. QuantuMDx's innovations support personalized medicine, making advanced diagnostics accessible in both developed and developing nations.
MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company’s clinical development pipeline includes lead drug candidate Pracinostat, a potential best-in-class, oral histone deacetylase (HDAC) inhibitor. Pracinostat has been tested in more than 150 patients in multiple Phase I and exploratory Phase II clinical trials, including advanced hematologic malignancies such as myelodysplastic syndrome, acute myeloid leukemia and myelofibrosis. The Company expects to initiate a randomized Phase II trial of Pracinostat in combination with standard-of-care in at least one hematologic malignancy toward the middle of 2013. In addition, MEI Pharma is developing two drug candidates derived from its isoflavone-based technology platform, ME-143 and ME-344. Results from a Phase I trial of intravenous ME-143 in heavily treated patients with solid refractory tumors were presented at the American Society of Clinical Oncology Annual Meeting in June 2012. A Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumors is ongoing.